RESOURCES

Treatment of obesity is revolutionized by the GLP-1 receptor agonists semaglutide (Wegovy^®, Novo Nordisk) and tirzepatide (Zepbound^®, Lilly).

Shorten the critical path to the clinic with SAR interrogation and scale-up strategies

Fragment-Based Drug Design (FBDD) presents a unique opportunity to identify novel binding sites for challenging targets, including membrane proteins.

Helicases are specialized and essential enzymes that unwind double -stranded DNA-DNA and RNA-DNA duplexes, which is critical for many vital cellular processes such as DNA replication, transcription, recombination, and ribosome biogenesis and repair.

Identifying potential clinical biomarkers is critical for any drug discovery program.

For rapid assessment of GPCR receptor pharmacology, Eurofins Discovery LeadHunter Services offers comprehensive functional cellbased assay solutions for 168 GPCR targets along with 73 orphan GPCRs, enabling profiling of pharmacophores, including psychedelics and controlled substances, against 55 different receptor families.

PIM3 kinase, which belongs to the Ca2+/calmodulin-dependent protein kinase (CaMK) group, exhibits serine/threonine kinase activity.

While checkpoint blockade antibodies are established cancer therapeutics, they have emerged as promising therapeutics for suppressing inflammation in autoimmune diseases.

Neurotoxicity is a major concern in central nervous system drug discovery and a frequent cause of attrition in clinical trials or approved drug withdrawal.

The PIM serine/threonine kinases (PIM1/PIM2/PIM3) are downstream effectors of ABL, JAK2 and Flt-3 oncogenes and are required for tumorigenesis.

Breast cancer brain metastasis is one of the most common forms of breast cancer metastasis and a major cause of morbidity and mortality.

.Access the results of OncoPanel^® screening profiles generated using industry benchmark reference agents for comparison with your therapeutic agents.